Market Trend Analysis: The Impact of Recent Advances on the Parkinson's Disease Market

The Parkinson's disease market is on track for considerable expansion over the coming years, driven by advancements in therapies and growing patient needs. This overview explores the market's projected size, key players shaping the industry, emerging trends, and the main segments that define this evolving healthcare area.

Projected Market Size and Growth of the Parkinson's Disease Market
The Parkinson's disease market is anticipated to experience robust growth, reaching $5.32 billion by 2030. This growth corresponds to a compound annual growth rate (CAGR) of 8.0%. Several factors are propelling this expansion, including the development of innovative dopamine and non-dopamine treatment options, an increasing aging population affected by the disease, rising use of deep brain stimulation techniques, heightened focus on personalized medicine, and the growing network of specialized neurology clinics. Key trends shaping the market over the forecast period include greater adoption of combination drug therapies, the rising use of deep brain stimulation procedures, expansion in early diagnosis and intervention methods, broader availability of multidisciplinary care programs for Parkinson's, and improved symptom control through tailored treatment plans.

Download a free report of the parkinson's disease market report:
https://www.thebusinessresearchcompany.com/report/parkinsons-disease-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Emerging Players Driving the Parkinson's Disease Market Forward
The competitive landscape of the Parkinson's disease market includes several prominent companies such as Roche Holding AG, AbbVie Inc., Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, UCB S.A., Eisai Co. Ltd., Kyowa Kirin Co. Ltd., Amneal Pharmaceuticals Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc., Sunovion Pharmaceuticals Inc., Intracellular Therapies Inc., Voyager Therapeutics Inc., Sage Therapeutics Inc., Adamas Pharmaceuticals Inc., Sun Pharma Advanced Research Company Ltd., Neuraly Inc., Mitsubishi Tanabe Pharma Corporation, Athira Pharma Inc., and VistaGen Therapeutics Inc. In a notable development, AbbVie Inc., a US-based pharmaceutical powerhouse, acquired Cerevel Therapeutics Holdings Inc. in August 2024. This strategic acquisition has strengthened AbbVie's neuroscience portfolio and addressed unmet needs in psychiatric and neurological disorders. Cerevel Therapeutics is recognized for its focus on developing therapies specifically for Parkinson's disease.

Key Trends Influencing the Parkinson's Disease Market
Innovations in medical devices have become a critical area of focus, with companies developing advanced wearable infusion pumps designed to improve patient convenience and treatment adherence. These devices are tubeless, wearable, and disposable, providing discreet and continuous insulin delivery without the hassle of external tubing. For example, GulfDrug LLC, a healthcare company based in the UAE, introduced the EOPatch in February 2023. This tubeless, wearable insulin pump can be controlled through Android and iOS smartphones using the Narsha app. The device supports up to 84 hours of uninterrupted insulin delivery, requires replacement only twice a week, and can communicate with compatible blood glucose meters via Bluetooth. The Narsha app is the first smartphone application approved for managing insulin delivery and diabetes data, streamlining diabetes care by eliminating the need for a separate controller.

View the full parkinson's disease market report:
https://www.thebusinessresearchcompany.com/report/parkinsons-disease-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Detailed Segmentation of the Parkinson's Disease Market
This report segments the Parkinson's disease market into several key categories to provide a thorough understanding of its scope:
1) Drug Class: Dopamine Agonists, Catechol-O-Methyltransferase Inhibitors, Monoamine Oxidase B Inhibitors, Anticholinergics, Carbidopa-Levodopa, and Other Drug Classes
2) Route of Administration: Oral, Injectable, Intestinal Infusion, Subcutaneous, and Other Routes
3) Distribution Channels: Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies
4) Patient Care Settings: Clinics and Hospitals

Further subdivision of drug classes includes:
- Dopamine Agonists: Ergot Derivatives and Non-Ergot Derivatives
- Catechol-O-Methyltransferase (COMT) Inhibitors: Entacapone, Tolcapone, Opicapone
- Monoamine Oxidase B (MAO-B) Inhibitors: Selegiline, Rasagiline, Safinamide
- Anticholinergics: Trihexyphenidyl, Benztropine, Procyclidine
- Carbidopa-Levodopa: Immediate-Release, Extended-Release, Inhaled, and Intestinal Gel Formulations
- Other Drug Classes: Amantadine and its derivatives, Adenosine A2A Receptor Antagonists, Glutamate Antagonists

Such detailed segmentation offers insight into the variety of treatment options and care settings that define the Parkinson's disease market landscape.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.